Therapeutic investigation into HER2 over-expressed and amplified NSCLC is in its early stage and there is a need for a more in-depth investigation into their oncogenic biology, as well as better defining biomarkers to allow further investigation in clinical trials. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.